Johnson Investment Counsel Inc. Sells 17,924 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Johnson Investment Counsel Inc. lessened its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 38.3% in the 3rd quarter, Holdings Channel.com reports. The fund owned 28,930 shares of the medical equipment provider’s stock after selling 17,924 shares during the period. Johnson Investment Counsel Inc.’s holdings in Zimmer Biomet were worth $2,850,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in ZBH. Key Financial Inc lifted its stake in Zimmer Biomet by 164.6% in the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 163 shares during the last quarter. Cullen Frost Bankers Inc. grew its stake in shares of Zimmer Biomet by 66.7% during the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 116 shares during the last quarter. Cary Street Partners Investment Advisory LLC raised its holdings in shares of Zimmer Biomet by 83.7% in the second quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 149 shares during the period. Root Financial Partners LLC bought a new stake in shares of Zimmer Biomet during the 3rd quarter worth approximately $31,000. Finally, Mather Group LLC. purchased a new position in Zimmer Biomet during the 3rd quarter valued at $36,000. 88.89% of the stock is currently owned by institutional investors.

Key Zimmer Biomet News

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q4 beat — ZBH reported EPS of $2.42 and revenue of ~$2.24B (up ~10.9% YoY), beating consensus and driven by strong demand for hip and knee devices. Reuters: Zimmer Biomet beats quarterly estimates
• Positive Sentiment: New buyback announced — Management unveiled a fresh repurchase program alongside the results, which supports the share price and signals confidence in cash generation. Yahoo Finance: ZBH up after earnings beat and buyback
• Positive Sentiment: Index/sector lift — The earnings beat contributed to broader healthcare index flows and was noted as lifting Russell 1000 Healthcare sentiment. Index/sector recognition can amplify demand for the stock. Kalkine: Beats estimates, lifts Russell 1000 Healthcare
• Positive Sentiment: Analyst moves — Several shops nudged targets or reaffirmed ratings (price-target increases to $98 at Citigroup and Wells Fargo; BTIG reiterated a $112 buy target), lending some near-term support. Benzinga: Analyst updates
• Neutral Sentiment: Guidance is conservative but roughly in-line — FY2026 EPS guidance was set at $8.30–$8.45 and revenue guidance around $8.4–$8.6B, essentially in line with consensus but underscored by cautious language that tempers upside expectations. MSN: Tops Q4 but measured on 2026 guidance
• Neutral Sentiment: U.S. salesforce overhaul — Management flagged a U.S. salesforce restructuring and transition that should improve execution long-term but adds near-term uncertainty and drove a cautious tone on the call. Yahoo Finance: Q4 deep dive — salesforce overhaul
• Negative Sentiment: Margins and headwinds — Management acknowledged margin pressure (some contraction noted in the quarter) and called out tariffs and cost dynamics as potential drags on 2026 profit expansion. These factors could limit upside to profitability. Zacks: Q4 earnings & margin commentary
• Negative Sentiment: Cautious management tone — While results beat, the measured guidance and commentary imply limited near-term upside and increased execution risk during the transition, which could cap multiple expansion. MSN: Q4 earnings call transcript

Wall Street Analyst Weigh In

Several analysts have recently weighed in on ZBH shares. Citigroup reiterated a “buy” rating on shares of Zimmer Biomet in a research report on Wednesday. Johnson Rice set a $112.00 price objective on shares of Zimmer Biomet in a report on Wednesday, November 5th. The Goldman Sachs Group cut shares of Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price objective for the company. in a research report on Friday, January 9th. Sanford C. Bernstein raised their target price on shares of Zimmer Biomet from $97.00 to $99.00 and gave the stock a “market perform” rating in a research report on Friday, January 9th. Finally, Canaccord Genuity Group decreased their price target on shares of Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating for the company in a research note on Monday, November 10th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $106.45.

Zimmer Biomet Trading Up 4.5%

NYSE ZBH opened at $95.51 on Thursday. Zimmer Biomet Holdings, Inc. has a one year low of $84.59 and a one year high of $114.44. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.39 and a current ratio of 1.98. The company has a market capitalization of $18.93 billion, a price-to-earnings ratio of 26.98, a price-to-earnings-growth ratio of 2.34 and a beta of 0.62. The company’s 50-day simple moving average is $90.01 and its two-hundred day simple moving average is $95.64.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The firm had revenue of $2.24 billion during the quarter, compared to analysts’ expectations of $2.22 billion. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.31 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, January 30th. Shareholders of record on Tuesday, December 30th were given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend was Tuesday, December 30th. Zimmer Biomet’s dividend payout ratio (DPR) is 27.12%.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.